CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Growth hormone +1 moredrug
Likely dose
Growth hormone 6mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00795210
NCT00795210N/ACompleted

Effects of Short-term Growth Hormone in HIV-infected Patients

Massachusetts General Hospital·interventional·Posted Nov 21, 2008·Updated Jan 8, 2014

In Brief

A clinical study evaluating Growth hormone and Growth Hormone Releasing Hormone for HIV Lipodystrophy. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The purpose of this study is to examine the short-term effects of two different doses of growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's secretion of growth hormone and the body's glucose metabolism. We hypothesize that growth hormone administration will alter the body's endogenous pulsatile growth hormone secretion and that higher dose growth hormone may decrease insulin sensitivity. We hypothesize that growth hormone releasing hormone will augment endogenous GH pulsatility and be neutral to insulin sensitivity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 21, 2008
Enrollment StartFeb 1, 2009
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.6 years ago

Interventions

Growth hormonedrug

Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks

Growth Hormone Releasing Hormonedrug

Tesamorelin (GHRH) 2mg SC QD x 2 weeks